Sequential Treatment with FLAG-IDA Salvage Chemotherapy Followed By Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed/Refractory Acute Leukemia
CONCLUSIONSFLAG-IDA HCT is a feasible strategy for relapsed/refractory acute leukemia patients that would have otherwise an extremely dismal prognosis. Yet, this regimen is associated with high early non-relapse mortality. Modifications of this regimen are warranted in order to reduce non-relapse mortality, without compromising the anti-leukemic effect.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - Category: Hematology Authors: Shargian-Alon, L., Wolach, O., Pasvolsky, O., Raanani, P., Yeshurun, M. Tags: 732. Clinical Allogeneic Transplantation: Results Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Acute Myeloid Leukemia | Brain | Chemotherapy | Hematology | Leukemia | Liver | Liver Transplant | Methotrexate | Myelodysplastic Syndrome | Neurology | Renal Failure | Restasis | Sarcomas | Stem Cell Therapy | Stem Cells | Toxicology | Transplants | Urology & Nephrology